Dyadic International, Inc.
Moat Score — Dyadic International, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Dyadic holds seven patent families (five national phase, two PCT), one issued U.S. patent, five pending U.S. applications, 18 additional international applications, and a Notice of Allowance for a flu-vaccine-production patent with expected protection through 2038, backed by two decades of fungal gene-expression platform development and trade-secret protection. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | The company claims its C1 platform uses media costing less than 1/20 of CHO media and produces proteins in about 12-14 days versus 41-54 days for CHO systems; if validated at commercial scale this would be a meaningful structural cost edge, though these figures are the company's own unverified assertions. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | As a pre-revenue platform licensor with no commercialized product, Dyadic has no ability to set or test prices in a market; its economics depend entirely on negotiated licensing and milestone terms. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A protein expression platform licensed to pharmaceutical and food-tech partners carries no network effect; the platform's value to one licensee does not increase as more licensees adopt it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Partners such as Phibro/Abic and Rubic One Health that have built development programs around C1-expressed proteins face some switching cost once a program is underway, but with no commercial product yet and most relationships still in early-stage collaboration, this lock-in remains limited. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The company states it is not aware of other firms pursuing a similar biopharma business model based on filamentous fungi, suggesting limited direct competition in this specific niche, but CHO-based systems dominate the broader mammalian protein-production market the company must ultimately compete against. |